Clinical trials: Recurrent Glioblastoma Multiforme(GBM)
Glioblastoma
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent…
- Trial name
- NCT03149003
- Testing
- DSP-7888 Dosing Emulsion, Bevacizumab
- Where
- 61 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- Sumitomo Pharma America, Inc.
Recurrent Glioblastoma
Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma
Increased glucose metabolism is characteristic for solid tumors. Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells.
- Trial name
- ERGO2 (NCT01754350)
- Testing
- calorie-restricted ketogenic diet and transient fasting, standard nutrition
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Glioblastoma
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in glioblastoma (a malignant tumor, or GBM), when…
- Trial name
- NCT03452579
- Testing
- Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- David Peereboom
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and determines the best dose of genetically modified neural stem cells and flucytosine when given together with leucovorin for treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT02015819
- Testing
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Anaplastic Astrocytoma, Glioblastoma
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
We are asked patients to take part in this study because they had recurrent (returned) (1st or 2nd) anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM).
- Trial name
- NCT00606008
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Glioblastoma
Bosutinib in Adult Patients With Recurrent Glioblastoma
For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells.
- Trial name
- NCT01331291
- Testing
- bosutinib
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma Multiforme
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
This randomized, non-comparative study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with recurrent glioblastoma.
- Trial name
- NCT01474239
- Testing
- bevacizumab [Avastin], fotemustine
- Where
- 10 sites in Italy
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).
- Trial name
- NCT04225039
- Testing
- INCMGA00012, INCAGN01876, SRS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Adult Glioblastoma, Depression
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
This clinical trial is studying magnetic resonance spectroscopy imaging in predicting response in patients to vorinostat and temozolomide in patients with recurrent, progressive, or newly diagnosed glioblastoma.
- Conditions
- Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
- Trial name
- NCT01342757
- Testing
- vorinostat, temozolomide, magnetic resonance spectroscopic imaging
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00892177
- Testing
- bevacizumab, dasatinib
- Where
- 305 sites in United States
- Volunteers
- 144 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Glioblastoma, Gliosarcoma
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
This study will determine the efficacy of the small molecule CDK4/6 inhibitor PD 0332991 (as measured by progression free survival at 6 months) in patients with recurrent glioblastoma multiforme or gliosarcoma who are Rb…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
- Trial name
- PD0332991 (NCT01227434)
- Testing
- PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Recurrent Glioblastoma, Recurrent Astrocytoma
PARP Inhibition for Gliomas (PI-4G or π4g)
The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
- Conditions
- Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma, Recurrent Glioma
- Trial name
- OU-SCC-PI-4G (NCT05297864)
- Testing
- Niraparib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Oklahoma
Neoplasms
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
First in human, open-label, dose escalation (Phase I) and expansion study (Phase 2a) of oral lisavanbulin (BAL101553) in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma…
- Trial name
- NCT02490800
- Testing
- Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people
- Sponsor
- Basilea Pharmaceutica
Glioblastoma, Gliosarcoma
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Primary objective: To determine the 6-month progression free survival of patients with recurrent glioblastoma multiforme (GBM) treated with Erlotinib plus Sirolimus.
- Trial name
- NCT00672243
- Testing
- Erlotinib + sirolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Glioblastoma, Recurrent Glioblastoma
VB-111 in Surgically Accessible Recurrent/Progressive GBM
This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
- Trial name
- NCT04406272
- Testing
- VB11, Surgery, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma, Glioma
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
- Trial name
- KING (NCT01986348)
- Testing
- Selinexor
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 76 people
- Sponsor
- Karyopharm Therapeutics Inc
Glioblastoma Multiforme, Malignant Gliomas
Sunitinib to Treat Recurrent Brain Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply them with nutrients and oxygen. Sunitinib blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the…
- Conditions
- Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
- Trial name
- NCT00923117
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)